SciELO - Scientific Electronic Library Online

 
vol.39 issue6Understanding the mechanisms of lung mechanical stressA cost-effective melting temperature assay for the detection of single-nucleotide polymorphism in the MBL2 gene of HIV-1-infected children author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Brazilian Journal of Medical and Biological Research

Print version ISSN 0100-879XOn-line version ISSN 1414-431X

Braz J Med Biol Res vol.39 no.6 Ribeirão Preto June 2006

https://doi.org/10.1590/S0100-879X2006000600002 

Braz J Med Biol Res, June 2006, Volume 39(6) 707-717 (Review)

Epidemiological and functional implications of molecular variants of human papillomavirus

L. Sichero and L.L. Villa

Instituto Ludwig de Pesquisa sobre o Câncer, São Paulo, SP, Brasil

Abstract
Text
References
Correspondence and Footnotes


Abstract

Human papillomavirus genomes are classified into molecular variants when they present more than 98% of similarity to the prototype sequence within the L1 gene. Comparative nucleotide sequence analyses of these viruses have elucidated some features of their phylogenetic relationship. In addition, human papillomavirus intratype variability has also been used as an important tool in epidemiological studies of viral transmission, persistence and progression to clinically relevant cervical lesions. Until the present, little has been published concerning the functional significance of molecular variants. It has been shown that nucleotide variability within the long control region leads to differences in the binding affinity of some cellular transcriptional factors and to the enhancement of the expression of E6 and E7 oncogenes. Furthermore, in vivo and in vitro studies revealed differences in E6 and E7 biochemical and biological properties among molecular variants. Nevertheless, further correlation with additional functional information is needed to evaluate the significance of genome intratypic variability. These results are also important for the development of vaccines and to determine the extent to which immunization with L1 virus-like particles of one variant could induce antibodies that cross-neutralize other variants.

Key words: Human papillomavirus, DNA sequencing, Oncogenic potential, Cervical cancer, Immunity, Epidemiology


Papillomavirus heterogeneity

The first evidence for the existence of different human papillomavirus (HPV) types was obtained in the early 1970's when it was observed that mRNA purified from plantar warts hybridized with DNA purified from other plantar warts but not from warts at other sites, including anogenital ones. In the following years, the genetic heterogeneity of HPV was confirmed by restriction fragment length polymorphism analysis and this was followed by an extensive and clear definition of HPV types based on DNA sequencing of different genes and the long control region (LCR) (1).

HPV types are defined as a viral genome with an L1 late gene sequence that is at least 10% dissimilar from that of any other type. To date more than 120 different HPV genotypes associated with infections in humans have been described. In addition, the Papillomavirus Nomenclature Committee has established that HPV genomes be classified into molecular variants when they present more than 98% of similarity to the prototype sequence in the L1 gene (1,2). Nevertheless, a recent study based on the comparison of the complete nucleotide sequence of 12 HPV-16 isolates from different phylogenetic branches showed that 4% of the full genome is variable within the 8 genes, and that 9.9% amino acid positions are variable (3). This study also revealed that the E4 and E5 genes are more variable than the LCR, which was previously reported to show as high as 5% dissimilarity among molecular variants (4). Furthermore, it was observed that E5 and E2 proteins had the highest proportion of non-synonymous/synonymous amino acid variations (3). Nevertheless, a strong inter-gene sequence co-variation has been observed for HPV (5).

The evolution of papillomaviruses is a matter of debate. Today, papillomaviruses are a taxonomic family of their own, Papillomavirinae, and comparative nucleotide sequence analysis of these viruses has elucidated some features of their phylogenetic relationship (1). Concerning HPV intratypic nucleotide heterogeneity, the most extensive studies have been conducted on HPV-16 (3-5), followed by HPVs 18 and 45 (6), HPVs 6 and 11 (7), HPVs 5 and 8 (8), and more recently HPVs 58 (9,10), 31, 33, 35, and 52 (11-13).

In the early 1990's, Ho and collaborators (4) observed that HPV-16 isolates could be distinguished by nucleotide heterogeneity within their genomes and suggested that molecular variants are generated over a large time span. It was then proposed that it would be possible to reconstruct viral phylogeny if all the intermediate genotypes were found. For this purpose, 301 HPV-16-positive cervical samples collected on the 5 continents had a fragment of the LCR sequenced and the data generated were used for the construction of a phylogenetic tree (4). In this analysis, 48 HPV-16 molecular variants characterized by 51 point mutations in 48 nucleotide positions were identified. The sequences generated were compared to the prototype genome which was isolated from a cervical cancer patient from Germany and was the first HPV-16 genome to be completely sequenced (1). It is important to highlight that the term prototype cannot be interpreted as indicative of an ancestral sequence. In fact, the ancestor of any HPV type is still unknown. The phylogenetic tree constructed is composed of 5 branches. The nomenclature of these branches reflects the geographical origin of most of the isolates within them. Variants from two of these branches were almost restricted to the African continent, which generated the denomination African 1 and 2 variants (4). Cervical samples containing African variants were also observed in other geographical regions at lower frequencies (0 to 9%) (5,14). Variants from a third branch were the only ones detected in different parts of Europe and therefore were included in the European branch. Isolates from this branch were also found in the majority of all other ethnic groups at frequencies ranging from 60% in Southeast Asia to 93% in North America (4). Interestingly, a high prevalence (>80%) of European variants was also observed in indigenous groups in Brazil and Argentina (4,15). A fourth branch was solely composed of Chinese and Japanese isolates, and therefore denominated Asian. Isolates from this branch were observed to be rare or even not found in other continents. A fifth branch, denominated Asian-American, was composed of a small fraction of all Asiatic and indigenous samples, and also of isolates from immigrant populations in America (4,5). Variants from this branch were detected only in Central and South America, and in Europe they were restricted to Spain. More recently, the highest prevalence of Asian-American variants ever was described in a Mexican cohort (88%) (12). These studies also suggested that the colonization of the American continent is reflected in its composition of HPV-16 variants. In fact, in samples from the city of São Paulo, southeast Brazil, we detected variants from all branches of geographical and phylogenetic relatedness, in agreement with the high level of miscegenation observed in this population (14). This was also observed in other studies conducted on multi-ethnic populations (16-18). Subsequent studies based on nucleotide sequence analysis of other viral genome regions (E6, L2, L1) expanded and complemented this phylogeny (5). Some variants are spread worldwide reflecting migration, whereas other variants appear to segregate according to ethnic group, suggesting evolution at these locations. A similar study was conducted on a worldwide collection of HPV-18-positive samples in which 37 molecular variants were described (6). These variants are characterized by point mutations in 25 nucleotide positions in comparison to the prototype sequence of HPV-18. The latter was isolated in Germany from a cervical cancer patient from Northeast Brazil and was fully sequenced (1). The nucleotide data generated with this collection led to the construction of a phylogenetic tree with a topology similar to that of HPV-16 (6).

The distribution and the small evolution of HPVs 16 and 18, and probably other HPV types suggest that these viruses evolved consecutively with their natural hosts over a period of a few million years. It was estimated that their diversity reflects an evolution of over 200,000 years from a precursor genome that may have originated in Africa (6,12).

Nucleotide variability and risk of cervical neoplasia

As described above, nucleotide sequence comparison has made possible the reconstruction of the origin and spread of HPVs in human populations. In addition, HPV intratype variability has also been used as an important tool in epidemiological studies of viral transmission, persistence and progression to clinically relevant cervical lesions. It has been observed that the same variants can be detected in cervical and anal smears of heterosexual women and homosexual men. Furthermore, a study conducted in Singapore detected the same variant only in 50% of sexual partners, suggesting that sexual transmission occurs with low infectivity (18).

Analysis of HPV isolates at the nucleotide level has also been suggested as a means to distinguish between persistent infection and acquisition of infection by different molecular variants. In multiple infection samples one major variant seems to persist over time while less frequent ones are transiently detected (19). In addition, data from the Canadian women's human immunodeficiency virus study group revealed that 8% of the women persistently infected by HPV-16 had transient infection by different molecular variants over time (20). However, other prospective studies found the same molecular variant of HPV-16 in 100% of the cases over follow-up time (14). The same was observed in infections of HPV types 33, 35, and 52 (11,13).

Different prospective and case-control studies are being conducted worldwide in order to analyze any possible association of increased risk of persistent infection and/or development of cervical lesion with specific variants of HPVs 16 and 18. However, because of limited sample size, individual variants are generally grouped into two categories based on nucleotide sequence variability, since it would be very difficult to detect any differences in risk based on individual variants within the group. Studies conducted in North America have revealed that non-European variants of HPV-16 are associated with increased risk for cervical intraepithelial lesion (18) and anal carcinoma in situ (21) in relation to the risk attributed to European variants. In a cohort study that is being conducted by us in São Paulo, Brazil (Ludwig/McGill study), non-European variants of HPVs 16 and 18 were also epidemiologically associated with an increased risk of persistent infection and development of cervical lesion (14). Furthermore, in case-control studies conducted on people from Costa Rica and Mexico, a higher prevalence of Asian-American variants was observed in samples isolated from cervical cancer as compared to normal ones (16,17). It is important to consider the multi-ethnic composition of the populations in which non-European variants are epidemiologically associated with an increased oncogenic potential (Table 1). In contrast, in populations from different parts of Europe the majority of HPV-16 molecular variants detected are from the European branch. A subset of the variants from this phylogenetic branch has a substitution in nucleotide position 350 (T®G) of the E6 gene that leads to a substitution of the amino acid 83 from valine to leucine. This mutation can also be detected in Asian-American but not in African variants (5). In a population from the United Kingdom, the 350G variant was suggested to be associated with an increased risk of persistent infection and cytological progression to cervical intra-epithelial neoplasia grade 2/3 (22). However, this epidemiologic finding was not observed in any of the European studies or in studies conducted on other continents and the data provided are still conflicting (5,23-27). It was also observed in the Japanese population that the E6 D25E variant, which is rarely found in Western countries, is more prevalent in invasive cancer samples. In addition, pre-cancerous lesions harboring this variant were less likely to regress than those with the HPV-16 prototype (28). The D25E E6 variant was the most frequent variation detected in Korean women. However, in this population, no significant difference was associated with increased risk for cervical cancer (24). In addition, the analysis of HPV-16 samples from Thailand women revealed that this E6 mutation coincided with a specific E7 mutation at residue 29 leading to a substitution from asparagine to serine (26). This E7 variant was also more frequent in cervical cancer samples compared to precursor lesions (29).

The nucleotide variability of the HPV-18 E2 gene suggested the existence of a subtype with decreased oncogenic potential (30). However, other studies analyzing nucleotide variability in the LCR, E2, or E6/E7 genes found no correlation between HPV-18 genotypes and lesion grade (31,32). Intratypic variability among HPV-18-positive specimens from North American and Mexican women suggested an association between specific variants and the histopathology findings. Non-European variants of HPVs 16 and 18 were commonly detected in adenocarcinomas (16,33). A possible hormonal mechanism was suggested to explain this finding (2).

The association of specific variants of HPVs 33, 35, 52, and 58 with the persistence of the infection and with the severity of the neoplasia has also been observed (9,11,13).

Taken together, these results indicate that, epidemiologically, the oncogenicity of molecular variants of HPVs 16, 18, and possibly other types, appears to vary not only geographically, but also with the ethnic origin of the populations under study. Hildesheim and collaborators (17) did not observe any ethnic differences between individuals infected with European or non-European HPV-16 variants, supporting the association between non-European variants and increased risk of cervical disease. On the other hand, the increased risk to acquire non-prototype-like variants of HPV-16 was reported to be associated with non-white compared to white individuals and also to non-white versus white
sex partners (18). Analysis of HPV-52 specimens showed that white women were more frequently infected with the prototype than with non-prototype variants. In contrast, women of African descent were more likely to be infected with non-prototype variants (11). The prototype of HPV-52 was detected in a biopsy sample from a woman living in the US. Other associations between race and infection by different molecular variants of HPVs 31, 33, and 35 have also been described (13). However, excluding the study by Hildesheim and collaborators (17), in all other studies, race classification was based on skin color which is not an ideal method to determine the degree of genetic relatedness among individuals. Further studies should include more women to confirm or rule out the association between ethnicity and viral polymorphism. Nevertheless, such ethnic contributions to the oncogenicity of HPV variants could be explained by different distributions of human leukocyte antigen (HLA) types across populations. HLA alleles are well known to have population-related distribution and could preferentially predispose women to establish and/or retain infection with particular HPV molecular variants.


Table 1. Epidemiologic associations between non-European variants of human papillomavirus-16 and increased risk for cervical neoplasia.

[View larger version of this table (50 K JPG file)]


Molecular variants and immune response

The most efficient immune response against disease caused by HPV is cell mediated. T lymphocyte recognition of HPV peptides is important for the control of infections and the development of cervical lesions. Thus, the presentation of viral peptides to T cells may be influenced by genetic variability of both HPV and HLA. An increased risk for cervical cancer associated with HPV-16 infection was attributed to carriers of HLA DRB1*1501/DQB1*0602 haplotypes among women from New Mexico. However, in Norway, HLA DRB1*0301-positive women had an increased risk of developing cervical intra-epithelial neoplasia grade 3 after infection by HPV-16 (34).

HPV 16 and 18 E2 variants were more frequently detected in women with HLA DR/DQ haplotypes 0401/0301 and 0101/0301 (32). Furthermore, it was observed in the Japanese population that DRB1*1501 and DQB1*0602 frequencies were significantly increased among patients infected with the HPV-16 prototype E6, and DRB1*1502 was associated with infection by the D25E variant (35). In addition, it was suggested that the G131 E6 molecular variant was associated with a worse prognosis in HLA-B7 women with cervical cancer. Computer models have suggested that the change within this E6 sequence alters an HLA-B7-binding peptide which could affect the cytotoxic T lymphocyte response. Nevertheless, the association between this variant, the HLA-B7 allele and prognosis was not further confirmed (36). More recently, Zehbe and collaborators (37) described the correlation between specific HLA I and II haplotypes and cervical cancer positive for the 350G E6 HPV-16 variant. These data are still very conflicting since other studies did not observe any association between HLA haplotypes and specific HPV-16 molecular variants (23). This suggests that other factors in addition to HLA polymorphism may be associated with acquisition of a variant in the development of cervical carcinoma. Large-scale epidemiologic studies are required to finally demonstrate the role of HLA in HPV-induced cervical disease.

It is also of interest to define alterations that may interfere with antigenic properties of the main capsid protein L1. For instance, variant 114K of HPV-16 assembles into virus-like particles (VLPs) in a heterologous expression system, whereas the prototype isolate is incapable of forming VLP. This difference is attributed to a single amino acid change of residue 202 of the L1 protein (38). It was also observed that the yield of VLPs produced varied within a range from 1 to 79 depending on the HPV-16 L1 variant used, and that mutations of residues 83 to 97 seemed to affect the level of L1 expression (39). In this study, variants which differed by up to 15 amino acids from the L1 prototype were used.

One or more amino acid alterations within the L1 protein of HPV-16 could represent a conformational change in the capsid protein and thus could also affect the conformation of epitopes relevant for viral neutralization. However, several studies have indicated that molecular variants of HPV-16 are cross-reactive since it was observed that sera from patients infected with different HPV-16 genotypes were capable of neutralizing VLPs of different HPV-16 variants (39,40). No differences in seroconversion rates between women infected with prototype and non-prototype variants were also observed (18). Furthermore, the absence of HPV-16 E6 and E7 antibodies was independent of the variant detected in cervical cancer patients (41). Even more important, it was reported that, from a vaccination perspective, molecular variants of HPV-16 belong to only one serotype (42). On the other hand, it was observed that L1 amino acid substitutions detected in cervical cancer patients and not normally found in natural variants could prevent VLP assembly. These substitutions were also unable to induce innate and adaptive immune responses in mice (43). This was suggested to be a mechanism for evasion from the immune system during carcinogenesis. Although lymphoproliferative responses to virions have been extensively described, very few studies have been conducted in order to map L1 epitopes. Strang and collaborators (44) defined the interaction between HPV-16 L1 peptides and the HLA class II DR4Dw4 allele. However, only one of the peptides described overlaps a substitution detected in molecular variants of the African 2 branch. Recent data from our laboratory also indicate that some alterations in E6/E7 proteins of natural HPV-16 variants seem to affect the proliferation of peripheral blood mononuclear cells (Souza PSA, personal communication). The relevance of these results for vaccine development remains to be shown. This same question also applies to cross-protection against different HPV types that could be involved by these vaccines. Some immune responses against HPV in both non-vaccinated and vaccinated people have been shown to be exquisitely type-specific; thus, cross-protection is unlikely to occur. This is the basis for second-generation vaccines encompassing up to six different high-risk HPV VLPs currently being developed.

Nucleotide variability and oncogenic potential

Differences in transformation activity of HPVs 16 and 18 have been ascribed to the LCR and E6/E7 early genes (45). Thus, it is reasonable to suppose that mutations in these regions may affect the clinical outcome of the infection. To date, little has been published concerning the functional significance of molecular variants (Table 2).

The early proteins E6 and E7 bind to and functionally inactivate the tumor suppressor proteins p53 and pRB, respectively, thus leading to the disruption of the DNA repair process and the cell-cycle machinery. Only E6 and E7 from high risk HPV types are capable of immortalizing primary human foreskin and of altering the functions of these tumor suppressor proteins. These observations indicated the importance of nucleotide variability in the oncogenic potential of different HPV types. Furthermore, although both HPVs 16 and 18 can abrogate terminal differentiation of keratinocytes induced by calcium and serum, this occurs with different efficiencies (45).

The LCR comprises about 10% of the viral genome and contains sequences important for the regulation of viral replication and transcription of early genes. The central segment of the LCR of high risk HPV genital types encloses an epithelial cell specific enhancer that contains several binding sites for viral (E2 and E1) and cellular transcription factors (AP-1, Sp-1, NF-1, Oct-1, TEF-1, YY-1, KRF-1, Skn-1a, and TFIID) (2). The activation of the main early promoter of HPV involves synergism between these proteins that vary in affinity for the different recognition sites throughout the LCR. Most of these factors stimulate transcription, although YY-1 can either repress or stimulate. In addition, the LCR contains glucocorticoid-responsive elements that were shown to mediate transcriptional activation by hormones in transient transfection experiments (46). The importance of chromatin organization in the transcriptional process of HPVs 16 and 18 has also been recognized (47).

Nucleotide changes within the LCR that overlaps cellular transcription binding sites have been extensively described (4,5,14). This variability could influence the binding affinity of the different transcription factors and thus affect viral transcription and replication. Not only mutations overlapping binding sites for the negative regulator YY-1 in the HPV-16 LCR are more commonly detected in cancer samples but also the promoter activity of these genomes is enhanced as compared to the prototype sequence (57). Luciferase activity assays showed that although HPV-16 European isolates had similar transcriptional activity, the Asian-American and the North-American 1 variants presented an enhanced activity as compared to European sequence of the HPV-16 prototype. On the other hand, one African variant tested exhibited promoter activity similar to that of the prototype (48,49). The LCR of the European variants analyzed in these studies had only few nucleotide changes as compared to the prototype. However, this was different for the non-European variants tested (4). Site-directed mutagenesis assays revealed that the enhancement observed in the promoter activity could be attributed to mutations in the 3' segment of the LCR (from nucleotide 7622 up) (48,49). The Asian-American and the North-American 1 variants contain a mutation at nucleotide position 7729 that is not present in the African or the other European genotypes. Nevertheless, neither of the tested nucleotide changes seemed to be responsible in itself for the enhanced transcriptional activity. In fact, the combination of nucleotide changes in the corresponding LCR could be responsible for the observed functional differences.

Concerning HPV-18 LCR intratypic nucleotide variability, we observed that the Asian-Amerindian B18-3 isolate was the most transcriptionally active relative to the activity of some European isolates tested (50). Furthermore, we observed that the HPV-18 prototype sequence was more active than the HPV-16 prototype. It has also been reported that a commonly detected substitution overlapping the Sp-1 binding site at the 3' end of the LCR enhances the transcriptional activity from the P105 HPV-18 main early promoter, since the binding of the Sp-1 protein to this sequence is also increased (31).

An extensive analysis of the E6 gene of different molecular variants of HPV-16 revealed that common amino acid changes identified overlap positions crucial for p53 interaction or for host immune surveillance (5). Stöppler and collaborators (51) analyzed three E6 molecular variants of HPV-16 and observed that the Asian-American protein surpassed the E6 European prototype sequence in its ability of stimulating the induction of differentiation-resistant colonies of human foreskin keratinocytes in cooperation with the E7 reference protein, and also of inducing p53 degradation in vitro. On the other hand, the African E6 variant analyzed showed reduced activity in both functions, suggesting that molecular variants differ in their biological and biochemical properties. More recently, it was observed that the 350G variant also surpassed the E6 prototype in enhancing the mitogen-activated protein kinase signaling and in the cooperative transformation with the deregulated Notch 1 pathway (52). Furthermore, it was observed that, in contrast to the E6 prototype sequence, the 350G variant inhibits oncogenic ras-mediated transformation suggesting that the quantitative differences in activation of mitogen-activated protein kinase signaling by the E6 protein and the 350G variant correlate with differences in the cooperative transformation by other signaling pathways.

Although it has been observed that the E7 protein is much conserved among different molecular variants, variability within this region could affect some of its known properties. In fact, in vitro mutational analysis has shown that the substitution of a single nucleotide in the E7 gene of HPVs 6 and 16 could affect the malignant transformation (58). It was also observed that E7 HPV-16 variants differ in their binding affinity to the pRB protein in a yeast two-hybrid system (53).

The association between specific variants of HPV-16 and the increased risk for cervical neoplasia could not be attributed to differences in the amino acid sequence of the E5 protein. However, a significantly greater usage of a common mammalian codon was observed among these variants (59). This event could confer a selective growth advantage on such variants since it has been suggested that codon usage may be important in the regulation of early HPV expression. However, similar in vitro transforming activities for HPV-16 E5 variant proteins were also described (54).

Another important issue that could influence the oncogenicity of the molecular variants is virus-driven regulation of transcription and replication. It was initially reported that the transcriptional transactivation potential of the E2 proteins from different HPV-16 variants differed only slightly among variants (49). More recently, it was suggested that in European variants the early E6/E7 gene transcription is repressed by the E2 protein and is frequently up-regulated by the interruption of the E2 gene during viral integration. In contrast, in tumor samples harboring Asian-American variants this gene was observed to be frequently retained (55). The association of Asian-American variants with retention of E1/E2 genes suggests that E2 nucleotide sequence variability could be an alternative mechanism up-regulating the expression of viral oncogenes. The HPV-16 Asian-American E2 protein has 16 non-synonymous mutations distributed along the gene as compared to the prototype sequence. However, none of these substitutions overlaps sequences of known consensus splicing sites located in the E2 gene. Casas and collaborators (60) also observed that Asian-American variants were associated with E1/E2-positive carcinomas with more than 50 viral copies/cell. This copy number was higher than that observed for European variants, suggesting that Asian-American variants may replicate better than European variants. In fact, European and African HPV-16 variants exhibit lower replication efficiency compared to the Asian-American isolates, which could, in turn, be attributable to their efficient expression of replicating factors E1 and E2 (56).

Most epidemiological and functional studies suggest that Asian-American variants of HPVs 16 and 18 are more oncogenic than European variants. Thus, these genotypes could constitute a marker of cervical cancer onset and progression and could partially explain why some lesions progress to cancer while others do not. It has been shown that nucleotide variability within the LCR could lead to an enhanced expression of the E6 and E7 oncogenes. Furthermore, the variability within these proteins themselves may also have functional significance, as suggested by some in vivo and in vitro studies. Efficient E1/E2 expression and elevated viral replication levels during persistent infection may also represent a risk factor in HPV-16 mediated oncogenesis. Further correlation with additional functional information is needed to evaluate the significance of intratypic genome variability.

Amino acid changes within some variants are located in epitopes critical for the immune response. Thus, vaccines developed against one variant may have a reduced efficacy in countries where these variants are less prevalent. To date, few studies have been conducted to address this issue among HPV-16 isolates. All of these studies have indicated that molecular variants of HPV-16 are serologically cross-reactive. Nevertheless, additional studies are necessary to evaluate epitopes that could be affected by mutations elsewhere in the genomes of these variants for the rational design of anti-HPV vaccines.


Table 2. Functional implications of human papillomavirus (HPV) gene variability.

[View larger version of this table (116 K JPG file)]


References

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.         [ Links ]

2. Bernard HU. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir Ther 2002; 7: 219-237.         [ Links ]

3. Chen Z, Terai M, Fu L, Herrero R, DeSalle R, Burk RD. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol 2005; 79: 7014-7023.         [ Links ]

4. Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67: 6413-6423.         [ Links ]

5. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71: 2463-2472.         [ Links ]

6. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, et al. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993; 67: 6424-6431.         [ Links ]

7. Heinzel PA, Chan SY, Ho L, O'Connor M, Balaram P, Campo MS, et al. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world. J Clin Microbiol 1995; 33: 1746-1754.         [ Links ]

8. Deau MC, Favre M, Orth G. Genetic heterogeneity among human papillomaviruses (HPV) associated with epidermodysplasia verruciformis: evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. Virology 1991; 184: 492-503.         [ Links ]

9. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002; 94: 1249-1253.         [ Links ]

10. Prado JC, Calleja-Macias IE, Bernard HU, Kalantari M, Macay SA, Allan B, et al. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 2005; 340: 95-104.         [ Links ]

11. Aho J, Hankins C, Tremblay C, Forest P, Pourreaux K, Rouah F, et al. Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis 2004; 190: 46-52.         [ Links ]

12. Calleja-Macias IE, Kalantari M, Huh J, Ortiz-Lopez R, Rojas-Martinez A, Gonzalez-Guerrero JF, et al. Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 2004; 319: 315-323.         [ Links ]

13. Gagnon S, Hankins C, Tremblay C, Forest P, Pourreaux K, Coutlee F. Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women. J Infect Dis 2004; 190: 1575-1585.         [ Links ]

14. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000; 81: 2959-2968.         [ Links ]

15. Picconi MA, Alonio LV, Sichero L, Mbayed V, Villa LL, Gronda J, et al. Human papillomavirus type-16 variants in Quechua aboriginals from Argentina. J Med Virol 2003; 69: 546-552.         [ Links ]

16. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001; 93: 1325-1330.         [ Links ]

17. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001; 93: 315-318.         [ Links ]

18. Xi LF, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee SK, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002; 11: 343-351.         [ Links ]

19. Xi LF, Demers W, Koutsky LA. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 1995; 172: 747-755.         [ Links ]

20. Mayrand MH, Coutlee F, Hankins C, Lapointe N, Forest P, de Ladurantaye M, et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000; 38: 3388-3393.         [ Links ]

21. Xi LF, Critchlow CW, Wheeler CM, Koutsky LA, Galloway DA, Kuypers J, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res 1998; 58: 3839-3844.         [ Links ]

22. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996; 69: 364-368.         [ Links ]

23. Bontkes HJ, van Duin M, de Gruijl TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, et al. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 1998; 78: 166-171.         [ Links ]

24. Kang S, Jeon YT, Kim JW, Park NH, Song YS, Kang SB, et al. Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women. Int J Gynecol Cancer 2005; 15: 107-112.         [ Links ]

25. Nindl I, Rindfleisch K, Teller K, Schneider A, Durst M. Cervical cancer, HPV 16 E6, variant genotypes, and serology. Lancet 1999; 353: 152.         [ Links ]

26. Vaeteewoottacharn K, Jearanaikoon P, Ponglikitmongkol M. Co-mutation of HPV16 E6 and E7 genes in Thai squamous cervical carcinomas. Anticancer Res 2003; 23: 1927-1931.         [ Links ]

27. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998; 352: 1441-1442.         [ Links ]

28. Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett 2000; 156: 159-165.         [ Links ]

29. Song YS, Kee SH, Kim JW, Park NH, Kang SB, Chang WH, et al. Major sequence variants in E7 gene of human papillomavirus type 16 from cervical cancerous and noncancerous lesions of Korean women. Gynecol Oncol 1997; 66: 275-281.         [ Links ]

30. Hecht JL, Kadish AS, Jiang G, Burk RD. Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 1995; 60: 369-376.         [ Links ]

31. Rose B, Steger G, Dong XP, Thompson C, Cossart Y, Tattersall M, et al. Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity. J Gen Virol 1998; 79 (Part 7): 1659-1663.         [ Links ]

32. Terry G, Ho L, Cuzick J. Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. Int J Cancer 1997; 73: 651-655.         [ Links ]

33. Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 2003; 63: 7215-7220.         [ Links ]

34. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002; 89: 229-240.         [ Links ]

35. Matsumoto K, Yasugi T, Nakagawa S, Okubo M, Hirata R, Maeda H, et al. Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 2003; 106: 919-922.         [ Links ]

36. Etherington IJ, Ellis JR, Luesley DM, Moffitt DD, Young LS. Histologic and immunologic associations of an HPV16 variant in LoSIL smears. Gynecol Oncol 1999; 72: 56-59.         [ Links ]

37. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 2003; 64: 538-542.         [ Links ]

38. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67: 6929-6936.         [ Links ]

39. Touze A, El Mehdaoui S, Sizaret PY, Mougin C, Munoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 1998; 36: 2046-2051.         [ Links ]

40. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St Louis ME, Han C, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995; 172: 1584-1587.         [ Links ]

41. Nindl I, Zumbach K, Pawlita M, Teller K, Schneider A, Durst M. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. J Infect Dis 2000; 181: 1764-1767.         [ Links ]

42. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001; 279: 361-369.         [ Links ]

43. Yang R, Wheeler CM, Chen X, Uematsu S, Takeda K, Akira S, et al. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol 2005; 79: 6741-6750.         [ Links ]

44. Strang G, Hickling JK, McIndoe GA, Howland K, Wilkinson D, Ikeda H, et al. Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity. J Gen Virol 1990; 71 (Part 2): 423-431.         [ Links ]

45. Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 1991; 181: 374-377.         [ Links ]

46. Chan WK, Klock G, Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989; 63: 3261-3269.         [ Links ]

47. Stunkel W, Huang Z, Tan SH, O'Connor MJ, Bernard HU. Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA. J Virol 2000; 74: 2489-2501.         [ Links ]

48. Kammer C, Warthorst U, Torrez-Martinez N, Wheeler CM, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol 2000; 81: 1975-1981.         [ Links ]

49. Veress G, Szarka K, Dong XP, Gergely L, Pfister H. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. J Gen Virol 1999; 80 (Part 4): 1035-1043.         [ Links ]

50. Sichero L, Franco EL, Villa LL. Different P105 promoter activities among natural variants of human papillomavirus type 18. J Infect Dis 2005; 191: 739-742.         [ Links ]

51. Stöppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996; 70: 6987-6993.         [ Links ]

52. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, et al. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol 2004; 78: 5934-5945.         [ Links ]

53. Choo KB, Wang TS, Huang CJ. Analysis of relative binding affinity of E7-pRB of human papillomavirus 16 clinical variants using the yeast two-hybrid system. J Med Virol 2000; 61: 298-302.         [ Links ]

54. Hsieh CH, Tsao YP, Wang CH, Han CP, Chang JL, Lee JY, et al. Sequence variants and functional analysis of human papillomavirus type 16 E5 gene in clinical specimens. Arch Virol 2000; 145: 2273-2284.         [ Links ]

55. Ordonez RM, Espinosa AM, Sanchez-Gonzalez DJ, Armendariz-Borunda J, Berumen J. Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription. J Gen Virol 2004; 85: 1433-1444.         [ Links ]

56. Hubert WG. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle. J Virol 2005; 79: 5914-5922.         [ Links ]

57. May M, Dong XP, Beyer-Finkler E, Stubenrauch F, Fuchs PG, Pfister H. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO J 1994; 13: 1460-1466.         [ Links ]

58. Sang BC, Barbosa MS. Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc Natl Acad Sci U S A 1992; 89: 8063-8067.         [ Links ]

59. Bible JM, Mant C, Best JM, Kell B, Starkey WG, Shanti RK, et al. Cervical lesions are associated with human papillomavirus type 16 intratypic variants that have high transcriptional activity and increased usage of common mammalian codons. J Gen Virol 2000; 81: 1517-1527.         [ Links ]

60. Casas L, Galvan SC, Ordonez RM, Lopez N, Guido M, Berumen J. Asian-American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int J Cancer 1999; 83: 449-455.         [ Links ]

Correspondence and Footnotes

Address for correspondence: L. Sichero, Instituto Ludwig de Pesquisa sobre o Câncer, Rua Prof. Antônio Prudente, 109, 4º andar, 01509-010 São Paulo, SP, Brasil. Fax: +55-11-2189-5036. E-mail: lsichero@ludwig.org.br

Research supported by NIH (No. CA70269) and FAPESP (No. 03/11410-3). Received September 23, 2005. Accepted March 29, 2006.

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License